Review Highlights Extracellular Vesicles as Critical Regulators and Potential Rejuvenation Vectors in Hematopoietic Aging

A comprehensive review details how extracellular vesicles coordinate bone marrow niche deterioration and blood stem cell decline during aging, highlighting opportunities for both biomarker development and therapeutic stem cell rejuvenation.

A new review published in Aging Cell synthesized recent advances in the biology of extracellular vesicles (EVs) within the aging hematopoietic system, illustrating their role in mediating intercellular communication between bone marrow (BM) niche cells and hematopoietic stem and progenitor cells (HSPCs).

The authors reported that during aging, senescent bone marrow stromal cells (MSCs) and osteoblasts secrete EVs with altered microRNA profiles (such as the miR-183 cluster) and depleted protective antioxidant payloads, which perpetuate niche dysfunction and drive myeloid-biased hematopoiesis.

The paper noted that in vivo models of telomerase deficiency (Tert-/- mice) exhibit a 36% reduction in circulating plasma EV abundance and lose physical telomeric DNA cargo, establishing a quantitative link between genomic instability and systemic vesicle depletion.

Conversely, youthful EVs delivered rejuvenating factors, such as Peroxiredoxins 1 and 2 and proliferating cell nuclear antigen (PCNA), which repaired bioenergetic decline and extended telomere length in aged bone marrow stromal cells in vitro.

The review establishes that hematopoietic aging is significantly driven by non-cell-autonomous mechanisms mediated by the local and systemic EV landscape, expanding therapeutic targets beyond cell-intrinsic HSC defects.

Vesicle uptake in the hematopoietic niche is characterized as a highly selective process regulated by vesicle-intrinsic surface signatures, including tetraspanins and integrins (such as CD9 associating with c-kit), rather than a passive, random accumulation.

Interventional studies compiled in the review demonstrate that systemic administration of youthful serum-derived EVs in rodent models successfully blunts chronic inflammaging, lowering circulating levels of IL-6, IL-1beta, and TNF-alpha, and partially restoring immune function.

The highlighted therapeutic potential of youthful EVs to rescue bioenergetics and reverse age-related stem cell decline supports the commercial development of platforms targeting mitochondrial transplantation and mitochondrial quality control in stem cells.

The finding that engineered juvenile EVs can activate mitophagy via the Pink1/Parkin pathway to restore bone marrow niche bioenergetics validates the focus on mitochondrial dynamics in managing age-associated hematologic and skeletal degeneration.

Longitudinal monitoring of circulating EV microRNA signatures (such as the enrichment of miR-29 and miR-96 and depletion of miR-146) could provide non-invasive biomarkers of multi-tissue stress and early clonal expansion before clinical manifestations of disease.

Competitive in vivo transplantation assays to evaluate whether exposure to rejuvenative youthful EVs can selectively suppress mutated clonal expansions (associated with ARCH or CHIP) over healthy HSPCs.

The adoption of three-dimensional bone marrow co-culture systems incorporating aged stromal populations and HSPCs to accurately model EV biogenesis and physiological target-cell interaction dynamics.